GSK exits Ebola vaccine R&D as J&J rival starts Uganda trialGlaxoSmithKline has licensed vaccines for Ebola to the US Sabin Vaccine Institute, just as a major trial of Share XGSK exits Ebola vaccine R&D as J&J rival starts Uganda trialhttps://pharmaphorum.com/news/gsk-exits-ebola-vaccine-rd-as-jj-rival-starts-uganda-trial/
EU clears GSK’s asthma drug Nucala in patient-friendly formatWith competition heating up in the severe asthma category, GlaxoSmithKline has a new EU approval that it hopes Share XEU clears GSK’s asthma drug Nucala in patient-friendly formathttps://pharmaphorum.com/news/eu-clears-gsks-asthma-drug-nucala-in-patient-friendly-format/
Symonds confirmed as new GSK chairman amid CEO’s business rethinkGlaxoSmithKline has confirmed that it has hired Jonathan Symonds as chairman, confirming press speculation that the former Novartis Share XSymonds confirmed as new GSK chairman amid CEO’s business rethinkhttps://pharmaphorum.com/news/symonds-confirmed-as-new-gsk-chairman-amid-ceos-business-rethink/
GSK takes aim at RA market, pitting otilimab against Pfizer and Sanofi rivals in phase 3GlaxoSmithKline (GSK) has made a serious play for the lucrative rheumatoid arthritis (RA) drug market, announcing the beginning Share XGSK takes aim at RA market, pitting otilimab against Pfizer and Sanofi rivals in phase 3https://pharmaphorum.com/news/gsk-takes-aim-at-ra-market-pitting-otilimab-against-pfizer-and-sanofi-rivals-in-phase-3/
ViiV’s Dovato HIV pill approved in EUViiV’s new daily HIV treatment has been approved in the EU, as the company aims to win over Share XViiV’s Dovato HIV pill approved in EUhttps://pharmaphorum.com/news/viivs-dovato-hiv-pill-approved-in-eu/
GSK consumer health sell-off ahead of Pfizer joint ventureGlaxoSmithKline (GSK) has begun the sale of some of its consumer health brands, hoping to raise around £1 Share XGSK consumer health sell-off ahead of Pfizer joint venturehttps://pharmaphorum.com/news/gsk-consumer-health-sell-off-ahead-of-pfizer-joint-venture/
EU regulators accept Novartis’ triple asthma comboEuropean regulators have accepted Novartis’ filing for a triple combination therapy for asthma known as QVM149, triggering payments Share XEU regulators accept Novartis’ triple asthma combohttps://pharmaphorum.com/news/eu-regulators-accept-novartis-triple-asthma-combo/
Shingles vaccine boosts GSK as generic Advair bitesGSK’s first quarter sales beat estimates, helped along by shingles vaccine Shingrix and partly offsetting the effect of Share XShingles vaccine boosts GSK as generic Advair biteshttps://pharmaphorum.com/news/shingles-vaccine-boosts-gsk-as-generic-advair-bites/
GSK and digital disruption: the pharmaphorum podcastDigital innovation and disruption in healthcare are the subject of this episode of the pharmaphorum podcast, for which Share XGSK and digital disruption: the pharmaphorum podcasthttps://pharmaphorum.com/podcast/gsk-digital-disruption
